Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-02-27 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the drug Dupixent. It details clinical trial results, regulatory status, and forward-looking statements. As it is a general regulatory announcement regarding product development and regulatory milestones that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2026-02-27 French
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the approval of the drug Dupixent. This is a standard corporate announcement regarding regulatory progress for a product candidate. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement, it falls under the general regulatory and corporate announcement category.
2026-02-27 English
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi and Regeneron announcing the FDA approval of their drug 'Dupixent' for a new indication (Allergic Fungal Rhinosinusitis). It details the clinical trial results (LIBERTY-AFRS-AIMS), the drug's mechanism, and regulatory status. This is a standard corporate announcement regarding product development and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into specific financial reporting categories like 10-K or Earnings Release.
2026-02-24 French
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Regeneron announcing the FDA approval of their drug, Dupixent, for a new indication (allergic fungal rhinosinusitis). It details the clinical trial results, the nature of the disease, and provides contact information for media and investor relations. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As a general corporate announcement regarding regulatory and product developments, it falls under the Regulatory Filings (RNS) category.
2026-02-24 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) and contains detailed tables listing share repurchase transactions by date, price, and volume. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS), which covers reports of a company buying back its own shares.
2026-02-23 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of transactions in own shares' and contains detailed tables listing daily volumes, purchase prices, and transaction references for Sanofi's share repurchase program. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2026-02-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.